Connection

Xinghuan Wang to Immunity, Cellular

Back to Details
This is a "connection" page, showing publications Xinghuan Wang has written about Immunity, Cellular.
Xinghuan Wang
Connection Strength
0.044
Immunity, Cellular
  1. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis. 2021 12; 21(12):1654-1664.
    View in: PubMed
    Score: 0.022
  2. SARS-CoV-2-specific immune response in COVID-19 convalescent individuals. Signal Transduct Target Ther. 2021 07 07; 6(1):256.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.